Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Registration Number
- NCT01734928
- Lead Sponsor
- Celgene
- Brief Summary
The purpose of this study is to compare the efficacy of the combination of pomalidomide, bortezomib and low dose dexamethasone to the combination of bortezomib and low dose dexamethasone in participants with relapsed/refractory multiple myeloma. This study will also assess how safe the combination of pomalidomide, bortezomib and low dose dexamethasone is compared to the combination of bortezomib and low dose dexamethasone.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 559
- Must be ≥ 18 years at the time of signing informed consent.
- Must have documented diagnosis of multiple myeloma and have measureable disease by serum and urine protein electrophoresis.
- Must have had at least 1 but no greater than 3 prior anti-myeloma regimens.
- Must have documented disease progression during or after their last anti-myeloma therapy.
- All subjects must have received prior treatment with a lenalidomide containing regimen for at least 2 consecutive cycles.
- Documented progressive disease during therapy or within 60 days of the last dose of a bortezomib-containing therapy under the 1.3 mg/m^2 dose twice weekly dosing schedule.
- Peripheral neuropathy Grade 3, Grade 4 or Grade 2 with pain within 14 days prior to randomization.
- Non-secretory multiple myeloma.
- Subjects with severe renal impairment requiring dialysis.
- Previous therapy with pomalidomide.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Pomalidomide, Bortezomib and Low Dose Dexamethasone Pomalidomide 4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression. Pomalidomide, Bortezomib and Low Dose Dexamethasone Bortezomib 4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression. Pomalidomide, Bortezomib and Low Dose Dexamethasone Dexamethasone 4 mg of Pomalidomide will be taken orally on Days 1-14 of a 21-day cycle along with 1.3 mg/m2 of Bortezomib administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression, and Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2,8, 9 of 21 days for cycles 9 and onward until disease progression. Bortezomib and Low Dose Dexamethasone Bortezomib 1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day \[≤ 75 years old\]or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression. Bortezomib and Low Dose Dexamethasone Dexamethasone 1.3 mg/m2 of Bortezomib will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression along with Dexamethasone 20 mg/day \[≤ 75 years old\]or 10 mg/day \[\> 75 years old\] orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
- Primary Outcome Measures
Name Time Method Progression Free Survival by Independent Response Adjudication Committee (IRAC) From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months Progression free survival (PFS) will be calculated as the time between the randomization and progressive disease (PD) or death.
Progressive Disease is defined as an Increase of ≥ 25% from nadir in:
* Serum M-component and/or (the absolute increase must be ≥ 0.5 g/dL)g
* Urine M-component and/or (the absolute increase must be ≥ 200 mg/24 hours)
* In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved FLC levels, the absolute increase must be \> 100 mg/dL.
* Bone marrow plasma cell percentage, the absolute % must be ≥ 10%h
* Definite development of new bone lesions or soft tissue plasmacytomas increase in the size of existing bone lesions or soft tissue plasmacytomas. -Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder.
- Secondary Outcome Measures
Name Time Method Overall Survival (OS) From randomization to date of death, up to approximately 65 months Overall survival (OS) is calculated as the time from randomization to death from any cause.
Number of Participants With Grade 3-4 Treatment Emergent Adverse Events (TEAE) From first dose to 28 days after the last dose (up to approximately 44 months Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.
Overall Response Rate by Independent Response Adjudication Committee (IRAC) From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months The ORR together with the relative proportions in each response category (ie, stringent CR \[sCR\], CR, very good PR \[VGPR\], PR, SD, and PD) by treatment using the IMWG criteria will be examined.
Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow
SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence
VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours
PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours
Progressive Disease: Please refer to Primary outcome measure for definition
SD: Not meeting criteria for CR, VGPR, PR, or progressive diseaseDuration of Response by Independent Response Adjudication Committee (IRAC) From randomization to progressive disease or death during the IRAC assessment period, up to approximately 42 months Duration of myeloma response is defined as the duration from the time when the IMWG response criteria are first met for sCR or CR or VGPR or PR until the first date the response criteria are met for PD or until the subject died from any cause, whichever occurs first.
Complete Response: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow
SCR: CR+ Normal FLC ratio and Absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence
VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine Mprotein level \< 100 mg per 24 hours
PR: ≥ 50% reduction of serum M-Protein and reduction in 24-hour urinary M-protein by ≥ 90% or to \< 200 mg per 24 hours
Progressive Disease: Please refer to Primary outcome measure for definition
SD: Not meeting criteria for CR, VGPR, PR, or progressive diseaseNumber of Participants With Grade 5 Treatment Emergent Adverse Events (TEAE) From first dose to 28 days after the last dose (up to approximately 44 months Treatment-emergent adverse events (TEAEs) are defined as any AE occurring or worsening on or after the first dose date of the study treatment and within 28 days after the last dose date.
Trial Locations
- Locations (321)
Western Kentucky Hematology and Oncology Group, PSC
🇺🇸Paducah, Kentucky, United States
Local Institution - 132
🇺🇸Bangor, Maine, United States
St. Agnes - Medical Center
🇺🇸Baltimore, Maryland, United States
Local Institution - 480
🇦🇹Vienna, Austria
Centre Hospitalier Lyon Sud
🇫🇷Pierre-Bénite Cedex, France
CHU La Miletrie
🇫🇷Poitiers Cedex, France
Local Institution - 504
🇫🇷Rennes, France
Local Institution - 481
🇦🇹Vienna, Austria
Local Institution - 304
🇨🇦Halifax, Canada
Broward Oncology Assoc.
🇺🇸Fort Lauderdale, Florida, United States
Local Institution - 442
🇩🇪Berlin, Germany
Local Institution - 455
🇫🇮Helsinki, Finland
Local Institution - 510
🇫🇮Hyvinkaa, Finland
CHRU Hopital Bretonneau
🇫🇷Tours cedex, France
Local Institution - 468
🇫🇷Tours cedex, France
Universitaetsklinikum Carl Gustav Carus
🇩🇪Dresden, Germany
UKT Universitaetsklinikum Tuebingen
🇩🇪Tuebingen, Germany
Local Institution - 487
🇬🇷Mezourlo, Greece
Local Institution - 462
🇮🇪Dublin, Ireland
Rambam Health Care Campus
🇮🇱Haifa, Israel
Policlinico S. Orsola - Malpighi
🇮🇹Bologna, Italy
Local Institution - 403
🇮🇹Modena, Italy
Azienda Unita Sanitaria Locale (Ausl) Pescara - Presidio Ospedaliero Di Pescara
🇮🇹Pescara, Italy
Medisch Centrum Leeuwarden
🇳🇱Leeuwarden, Netherlands
Local Institution - 407
🇵🇱Chorzow, Poland
Oddzial Kliniczny Kliniki Hematologii
🇵🇱Krakow, Poland
Local Institution - 408
🇹🇷Ankara, Turkey
Local Institution - 474
🇹🇷Istanbul, Turkey
Local Institution - 419
🇹🇷Izmir, Turkey
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center Department of Hematology
🇮🇱Tel Aviv, Israel
Ospedale Ferrarotto
🇮🇹Catania, Italy
Szpital Uniwersytecki nr 2 im dr. Jana Biziela
🇵🇱Bydgoszcz, Poland
Local Institution - 466
🇵🇹Lisboa, Portugal
Hospital de Santo Antonio- Porto
🇵🇹Porto, Portugal
Local Institution - 451
🇮🇹Pavia, Italy
Azienda Ospedaliera San Giovanni Battista
🇮🇹Torino, Italy
Local Institution - 460
🇮🇹Rome, Italy
A.O.U.S. Giovanni e Ruggi d'Aragona UOC UTIC
🇮🇹Salerno, Italy
Local Institution - 402
🇮🇹Terni, Italy
Local Institution - 453
🇮🇹San Giovanni Rotondo, Italy
Local Institution - 514
🇳🇱Groningen, Netherlands
Erasmus Medical Center
🇳🇱Rotterdam, Netherlands
Kopernik Memorial Hospital
🇵🇱Lodz, Poland
Local Institution - 437
🇵🇱Poznan, Poland
Ege University Medical School
🇹🇷Izmir, Turkey
Local Institution - 404
🇹🇷Trabzon, Turkey
Local Institution - 186
🇺🇸Bronx, New York, United States
Southern Cancer Center
🇺🇸Mobile, Alabama, United States
Sutter Pacific Medical Foundation
🇺🇸Santa Rosa, California, United States
University of Iowa
🇺🇸Iowa City, Iowa, United States
St. John's Clinic Cancerand Hematology - Springfield
🇺🇸Springfield, Missouri, United States
Eastern Institute of Medical Sciences
🇺🇸Greenville, North Carolina, United States
Metro MN CCOP
🇺🇸Saint Louis Park, Minnesota, United States
Essentia Health Duluth CCOP
🇺🇸Duluth, Minnesota, United States
New York Medical College
🇺🇸Valhalla, New York, United States
Aarhus University Hospital
🇩🇰Aarhus, Denmark
Odense University Hospital
🇩🇰Odense, Denmark
Local Institution - 178
🇺🇸Detroit, Michigan, United States
Worcestershire Acute Hospitals NHS Trust
🇬🇧Worcester, United Kingdom
University of Arizona Cancer Center
🇺🇸Tucson, Arizona, United States
University Cancer Institute
🇺🇸Boynton Beach, Florida, United States
Marin Oncology Associates
🇺🇸Greenbrae, California, United States
Lynn Cancer Institute
🇺🇸Boca Raton, Florida, United States
Local Institution - 153
🇺🇸Southington, Connecticut, United States
USC Norris Comprehensive Cancer Center
🇺🇸Los Angeles, California, United States
Cancer Care of Maine
🇺🇸Bangor, Maine, United States
Billings Clinic
🇺🇸Billings, Montana, United States
Swedish Cancer Inst
🇺🇸Seattle, Washington, United States
West Virginia University CTRU
🇺🇸Morgantown, West Virginia, United States
Wenatchee Valley Hospital and Clinics
🇺🇸Wenatchee, Washington, United States
Huntsman Cancer Institute at the University of Utah
🇺🇸Salt Lake City, Utah, United States
Medical Oncology Associates
🇺🇸Spokane, Washington, United States
Local Institution - 139
🇺🇸Morgantown, West Virginia, United States
Local Institution - 523
🇦🇹St. Pölten, Austria
Hospital St. Polten
🇦🇹St. Pölten, Austria
Medical University of Vienna
🇦🇹Vienna, Austria
Local Institution - 308
🇨🇦Oshawa, Ontario, Canada
Centre De Sante Et De Services Sociaux De Rimouski-Neigette
🇨🇦Rimouski, Quebec, Canada
Wilhelminenspital-Center for Hematology and Oncology
🇦🇹Vienna, Austria
RSM Durham Regional Cancer Center - Lakeridge Health Oshawa
🇨🇦Oshawa, Ontario, Canada
Local Institution - 447
🇩🇰Aarhus, Denmark
CSSS Champlain Charles LeMoyne
🇨🇦Greenfield Park, Quebec, Canada
Local Institution - 499
🇩🇰Vejle, Denmark
Vejle Hospital
🇩🇰Vejle, Denmark
Copenhagen University Hospital Rigshosptalet
🇩🇰Copenhagen, Denmark
Local Institution - 400
🇩🇰Odense, Denmark
Helsinki University Central Hospital
🇫🇮Helsinki, Finland
Centre Hospitalier William Morey
🇫🇷Chalon sur Saone, France
Local Institution - 498
🇫🇷Chalon sur Saone, France
GH Institut Catholique St Vincent
🇫🇷Lille, France
Local Institution - 476
🇫🇷Lille, France
Hyvinkaa Hospital
🇫🇮Hyvinkaa, Finland
CHU Hotel
🇫🇷Grenoble Cedex 09, France
Local Institution - 483
🇫🇷Grenoble Cedex 09, France
Local Institution - 486
🇫🇷Nantes, France
CHRU de Lille-Hopital Claude Huriez
🇫🇷Lille, France
Groupement Hospitalier Universitaire Est - Hopital Saint-Antoine
🇫🇷Paris, France
ChariteUniversitatsmedizinCampus Benjamin Franklin
🇩🇪Berlin, Germany
Local Institution - 497
🇫🇷Pierre-Bénite Cedex, France
CHRU Rennes
🇫🇷Rennes, France
Local Institution - 475
🇩🇪Essen, Germany
Local Institution - 417
🇩🇪Dresden, Germany
Local Institution - 496
🇩🇪Freiburg, Germany
Universitatsklinikum Freiburg
🇩🇪Freiburg, Germany
University of Heidelberg
🇩🇪Heidelberg, Germany
Universitaetsklinikum EssenInnere Klinik und Poliklinik
🇩🇪Essen, Germany
Local Institution - 410
🇩🇪Tuebingen, Germany
University General Hospital of Larissa
🇬🇷Mezourlo, Greece
George Papanikolaou General Hospital of Thessaloniki
🇬🇷Thessloniki, Greece
Local Institution - 430
🇩🇪Heidelberg, Germany
Local Institution - 422
🇬🇷Athens, Greece
Local Institution - 484
🇬🇷Athens, Greece
General Hospital of Athens Evangelismos
🇬🇷Athens, Greece
Local Institution - 465
🇬🇷Thessloniki, Greece
Local Institution - 413
🇮🇪Galway, Ireland
University College Hospital Galway
🇮🇪Galway, Ireland
Local Institution - 457
🇮🇱Jerusalem, Israel
USC Ematologia, Azienda Ospedaliera Papa Giovanni XXIII
🇮🇹Bergamo, Italy
Local Institution - 456
🇮🇹Bologna, Italy
IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
Azienda Ospedaliera di Reggio Emilia - Arcispedale Santa Maria Nuova
🇮🇹Reggio Emilia, Italy
Local Institution - 414
🇮🇹Reggio Emilia, Italy
La Sapienza, University of Rome
🇮🇹Rome, Italy
Local Institution - 415
🇮🇹Catania, Italy
Local Institution - 441
🇮🇹Pescara, Italy
Local Institution - 459
🇮🇹Salerno, Italy
IRCCS Casa Sollievo della Sofferenza
🇮🇹San Giovanni Rotondo, Italy
Azienda Ospedaliera S Maria di Terni
🇮🇹Terni, Italy
Local Institution - 401
🇮🇹Torino, Italy
Japan Red Cross Medical Center
🇯🇵Shibuya-ku, Japan
Local Institution - 623
🇯🇵Shibuya-ku, Japan
Local Institution - 620
🇯🇵Hitachi, Ibaraki, Japan
Local Institution - 626
🇯🇵Okayama, Japan
Local Institution - 625
🇯🇵Kamogawa, Japan
Okayama Medical Center
🇯🇵Okayama, Japan
Local Institution - 622
🇯🇵Tachikawa, Japan
National Hospital Organization Disaster Medical Center
🇯🇵Tachikawa, Japan
Universitair Medisch Centrum Groningen
🇳🇱Groningen, Netherlands
Local Institution - 494
🇳🇱Rotterdam, Netherlands
Local Institution - 412
🇳🇴Oslo, Norway
Oslo universitetssykehus, Rikshospitalet
🇳🇴Oslo, Norway
St Olavs Hospital
🇳🇴Trondheim, Norway
Local Institution - 411
🇵🇱Brzozow, Poland
Zespol Szpitali Miejskich
🇵🇱Chorzow, Poland
Klinika Hematologii Akademii Medycznej w Gdansku
🇵🇱Gdansk, Poland
Local Institution - 463
🇵🇱Gdansk, Poland
Szpital Specjalistyczny w Brzozowie
🇵🇱Brzozow, Poland
Local Institution - 440
🇵🇱Krakow, Poland
Hospital de Braga
🇵🇹Braga, Portugal
Instituto Portugues de Oncologia de Lisboa, Francisco Gentil
🇵🇹Lisboa, Portugal
Local Institution - 418
🇵🇱Lodz, Poland
Klinika Hematoonkologii i Transplantacji Szpiku
🇵🇱Lublin, Poland
Local Institution - 454
🇵🇹Lisboa, Portugal
Hospital de Santa Maria
🇵🇹Lisboa, Portugal
Local Institution - 464
🇵🇹Porto, Portugal
Local Institution - 473
🇵🇹Lisbon, Portugal
Local Institution - 425
🇵🇹Porto, Portugal
Ad-Vance Medical Research, LLC
🇵🇷Ponce, Puerto Rico
Local Institution - 521
🇷🇺Moscow, Russian Federation
Local Institution - 520
🇷🇺Nizhny Novgorod, Russian Federation
Moscow State Healthcare Institution City clinical hospital n.a. S.P.Botkin
🇷🇺Moscow, Russian Federation
State Budgetary Healthcare Institution of Nizhniy Novgorod Region
🇷🇺Nizhny Novgorod, Russian Federation
Local Institution - 517
🇷🇺Moscow, Russian Federation
Local Institution - 423
🇪🇸Badalona (Barcelona), Spain
Hospital 12 de Octubre
🇪🇸Madrid, Spain
Russian Research Institute of Hematology and Transfusiology of the Federal Biomedical Agency
🇷🇺Saint Petersburg, Russian Federation
Local Institution - 424
🇪🇸Barcelona, Spain
Local Institution - 526
🇪🇸Orense, Spain
Local Institution - 502
🇪🇸Murcia, Spain
Local Institution - 492
🇪🇸Sevilla, Spain
Clinica Universidad de Navarra
🇪🇸Pamplona, Spain
Local Institution - 478
🇸🇪Gothenburg, Sweden
Sahlgrenska University Hospital
🇸🇪Gothenburg, Sweden
Local Institution - 434
🇪🇸Pamplona, Spain
Local Institution - 426
🇸🇪Falun, Sweden
Complejo Hospitalario Nuestra Senora de Valme
🇪🇸Sevilla, Spain
Sunderby Sjukhus
🇸🇪Luleå, Sweden
Local Institution - 471
🇸🇪Stockholm, Sweden
Falu lasarett
🇸🇪Falun, Sweden
Local Institution - 429
🇸🇪Luleå, Sweden
Karolinska University
🇸🇪Stockholm, Sweden
Ankara University Medical Faculty Cebeci Hospital
🇹🇷Ankara, Turkey
Medstar Antalya Hospital
🇹🇷Antalya, Turkey
Eskisehir Osmangazi University
🇹🇷Eskisehir, Turkey
Gaziantep University
🇹🇷Gaziantep, Turkey
Local Institution - 428
🇹🇷Ankara, Turkey
Local Institution - 488
🇹🇷Antalya, Turkey
Local Institution - 445
🇹🇷Istanbul, Turkey
University College London Hospitals
🇬🇧London, United Kingdom
Local Institution - 461
🇬🇧London, United Kingdom
Gazi Universitesi Tip Fakultesi Hastanesi
🇹🇷Ankara, Turkey
Istanbul University Faculty of Medicine
🇹🇷Istanbul, Turkey
Local Institution - 406
🇬🇧Edinburgh Scotland, United Kingdom
Local Institution - 515
🇬🇧Plymouth, United Kingdom
Southampton General Hospital
🇬🇧Southampton, United Kingdom
Local Institution - 409
🇹🇷Ankara, Turkey
Local Institution - 479
🇬🇧Canterbury Kent, United Kingdom
Kings College Hospital
🇬🇧London, United Kingdom
Ankara Universitesi Tip Fakultesi
🇹🇷Ankara, Turkey
Local Institution - 420
🇹🇷Eskisehir, Turkey
Local Institution - 421
🇹🇷Gaziantep, Turkey
Local Institution - 512
🇬🇧Oxford, United Kingdom
The Royal Bournemouth Hospital
🇬🇧Bournemouth, United Kingdom
Istanbul Universitesi Cerrahpasa Tip Fakultesi
🇹🇷Istanbul, Turkey
Karadeniz Teknik Universitesi Tip Fakultesi Farabi Hastanesi
🇹🇷Trabzon, Turkey
Kent and Canterbury Hospital
🇬🇧Canterbury Kent, United Kingdom
Western General Hospital
🇬🇧Edinburgh Scotland, United Kingdom
Local Institution - 500
🇬🇧Sheffield, United Kingdom
Local Institution - 493
🇬🇧Southampton, United Kingdom
University Hospital of North Staffordshire Nhs Trust - City General Hospital
🇬🇧Stoke-On-Trent, United Kingdom
Local Institution - 405
🇬🇧Swansea, United Kingdom
Singleton Hospital
🇬🇧Swansea, United Kingdom
New Cross Hospital
🇬🇧Wolverhampton, United Kingdom
Complejo Hospitalario De Orense
🇪🇸Orense, Spain
Hospital de Basurto-Osakidetza
🇪🇸Bilbao, Spain
Local Institution - 452
🇪🇸Madrid, Spain
Hospital Morales Meseguer
🇪🇸Murcia, Spain
Hospital Universitario y Politecnico La Fe
🇪🇸Valencia, Spain
University of Colorado Cancer Center
🇺🇸Aurora, Colorado, United States
Providence Portland Medical Center
🇺🇸Portland, Oregon, United States
Local Institution - 136
🇺🇸Milwaukee, Wisconsin, United States
Medical College of Wisconsin
🇺🇸Milwaukee, Wisconsin, United States
Arizona Oncology
🇺🇸Tucson, Arizona, United States
Beth Israel Deaconess Medical Center
🇺🇸Boston, Massachusetts, United States
City Clinical Hospital 52
🇷🇺Moscow, Russian Federation
Med Univ of South Carolina
🇺🇸Charleston, South Carolina, United States
University of California San Francisco Fresno Campus
🇺🇸Fresno, California, United States
Northwest Georgia Oncology Centers, PCWilliam S. Gibbons Center Research Institute
🇺🇸Marietta, Georgia, United States
Alta Bates Comprehensive Cancer Center
🇺🇸Berkeley, California, United States
Moore UCSD Cancer Center
🇺🇸La Jolla, California, United States
Cancer Center of Central Connecticut
🇺🇸Southington, Connecticut, United States
Broward Oncology Associates PA
🇺🇸Fort Lauderdale, Florida, United States
Local Institution - 135
🇺🇸Marietta, Georgia, United States
University of Chicago
🇺🇸Chicago, Illinois, United States
Investigative Clinical Research of Indiana, LLC
🇺🇸Indianapolis, Indiana, United States
Center for Cancer and Blood Disorders
🇺🇸Bethesda, Maryland, United States
Medstar Health Research Institute
🇺🇸Hyattsville, Maryland, United States
Local Institution - 100
🇺🇸Boston, Massachusetts, United States
Local Institution - 298
🇺🇸Boston, Massachusetts, United States
Henry Ford Medical Center - New Center One
🇺🇸Detroit, Michigan, United States
Columbia Comprehensive
🇺🇸Jefferson City, Missouri, United States
Cancer and Hematology Centers of Western Michigan
🇺🇸Grand Rapids, Michigan, United States
Beaumont Cancer Center
🇺🇸Royal Oak, Michigan, United States
Detroit Clinical Research Center
🇺🇸Lansing, Michigan, United States
Southeast Nebraska Cancer Center
🇺🇸Lincoln, Nebraska, United States
St John's Mercy Medical Center
🇺🇸Saint Louis, Missouri, United States
Hematology-Oncology Associates of NNJ, P
🇺🇸Morristown, New Jersey, United States
CarePoint Health Research Institute
🇺🇸Jersey City, New Jersey, United States
Somerset Hematology-Oncology Associates
🇺🇸Somerville, New Jersey, United States
Mount Sinai Hospital
🇺🇸New York, New York, United States
Stony Brook University
🇺🇸Stony Brook, New York, United States
Local Institution - 111
🇺🇸Canton, Ohio, United States
Gabrail Cancer Center Research
🇺🇸Canton, Ohio, United States
Boice-Willis Clinic P.A.
🇺🇸Rocky Mount, North Carolina, United States
CHRU Hotel Dieu
🇫🇷Nantes, France
MetroHealth Medical Systems
🇺🇸Cleveland, Ohio, United States
University of Toledo Medical Center
🇺🇸Toledo, Ohio, United States
Mid Ohio Oncology Hematology Inc
🇺🇸Columbus, Ohio, United States
Spartanburg Regional Healthcare System - Gibbs Cancer Center & Research Institute
🇺🇸Spartanburg, South Carolina, United States
University of Tennessee Medical Center - Cancer Institute
🇺🇸Knoxville, Tennessee, United States
Prairie Lakes Health Care System
🇺🇸Watertown, South Dakota, United States
Local Institution - 114
🇺🇸Dallas, Texas, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
Local Institution - 103
🇺🇸Fort Sam Houston, Texas, United States
Brooke Army Medical Center Francis Street Medical Center
🇺🇸Fort Sam Houston, Texas, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Utah Cancer Specialist
🇺🇸Salt Lake City, Utah, United States
Joe Arrington Cancer Research and Treatment Center
🇺🇸Lubbock, Texas, United States
Local Institution - 130
🇺🇸Houston, Texas, United States
Northwest Cancer Center
🇺🇸Houston, Texas, United States
Local Institution - 506
🇩🇰Copenhagen, Denmark
Centre Hospitalier Universitaire de Sherbrooke-Hospital Fleurimont
🇨🇦Sherbrooke, Quebec, Canada
Local Institution - 307
🇨🇦Sherbrooke, Quebec, Canada
Centre Hospitalier de la cote basque
🇫🇷Bayonne, France
Local Institution - 516
🇫🇷Poitiers Cedex, France
Institut Universitaire du Cancer de Toulouse (IUCT) - Oncopole
🇫🇷Toulouse Cedex, France
University of Athens Medical school - Regional General Hospital
🇬🇷Athens, Greece
Meir Medical Center
🇮🇱Kfar-Saba, Israel
Kameda Medical Center
🇯🇵Kamogawa, Japan
Hitachi General Hospital
🇯🇵Hitachi, Ibaraki, Japan
Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie
🇵🇱Warszawa, Poland
Local Institution - 448
🇵🇱Warszawa, Poland
Oddzial Hematologii i Chorob Rozrostowych Ukladu Krwiotworczego
🇵🇱Poznan, Poland
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Hospital Universitari Germans Trias i Pujol Can Ruti
🇪🇸Badalona (Barcelona), Spain
Instituto Portugues de Oncologia do Porto, Francisco Gentil
🇵🇹Porto, Portugal
Sundsvalls sjukhus- Medicinkliniken
🇸🇪Sundsvall, Sweden
Local Institution - 490
🇬🇧London, United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital
🇬🇧Sheffield, United Kingdom
University of Oxford
🇬🇧Oxford, United Kingdom
Derriford Hospital Plymouth Oncology Centre Clinical Trials Unit
🇬🇧Plymouth, United Kingdom
Local Institution - 482
🇬🇧Wolverhampton, United Kingdom
Local Institution - 436
🇬🇧Worcester, United Kingdom
Tulane University Medical Center
🇺🇸New Orleans, Louisiana, United States
Kansas City VA Medical Center University of Kansas Medical Center
🇺🇸Kansas City, Missouri, United States
University of Florida
🇺🇸Gainesville, Florida, United States
University of Modena
🇮🇹Modena, Italy
George Washington Medical Center
🇺🇸Washington, District of Columbia, United States
Alves Domenech Oncology and Hematology Clinic
🇺🇸Hollywood, Florida, United States
Palm Beach Cancer Institute, LLC
🇺🇸West Palm Beach, Florida, United States
Local Institution - 299
🇺🇸Boston, Massachusetts, United States
Massachusetts General Hospital
🇺🇸Boston, Massachusetts, United States
Dana Farber Cancer Institute
🇺🇸Boston, Massachusetts, United States
Local Institution - 125
🇺🇸Bethesda, Maryland, United States
Local Institution - 301
🇨🇦Greenfield Park, Quebec, Canada
Local Institution - 469
🇫🇷Bayonne, France
Mater Misericordiae University Hospital
🇮🇪Dublin, Ireland
Local Institution - 431
🇮🇪Dublin, Ireland
St James Hospital
🇮🇪Dublin, Ireland
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Local Institution - 433
🇮🇱Kfar-Saba, Israel
Local Institution - 449
🇮🇹Bergamo, Italy
Avera Research Institute
🇺🇸Sioux Falls, South Dakota, United States
Local Institution - 167
🇺🇸Watertown, South Dakota, United States
Local Institution - 439
🇵🇱Lublin, Poland
Local Institution - 450
🇵🇹Braga, Portugal
Fundacao Champalimaud
🇵🇹Lisbon, Portugal
University of Wisconsin
🇺🇸Madison, Wisconsin, United States
Montefiore Medical Center
🇺🇸Bronx, New York, United States
Queen Elizabeth II Health Sciences Centre
🇨🇦Halifax, Canada